Skip to main content
SpringerLink
Log in

Mineralocorticoid-receptor blockade, hypertension and heart failure

  • Viewpoint
  • Published:

From Nature Clinical Practice Endocrinology & Metabolism

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pitt B et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341: 709–717

    Article  CAS  Google Scholar 

  2. Pitt B et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309–1321

    Article  CAS  Google Scholar 

  3. Pitt B et al. (2003) Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108: 1831–1838

    Article  CAS  Google Scholar 

  4. Rocha R et al. (2002) Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143: 4828–4836

    Article  CAS  Google Scholar 

  5. Juurlink D et al. (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543–551

    Article  CAS  Google Scholar 

  6. Bozkurt B et al. (2003) Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 41: 211–214

    Article  CAS  Google Scholar 

  7. Levy D et al. (2004) Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 89: 2736–2740

    Article  CAS  Google Scholar 

  8. Funder JW et al. (1988) Mineralocorticoid action: target-tissue specificity is enzyme, not receptor, mediated. Science 242: 583–585

    Article  CAS  Google Scholar 

  9. Funder JW and Myles K (1996) Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology 137: 5264–5268

    Article  CAS  Google Scholar 

  10. Funder JW (2004) Is aldosterone bad for the heart? Trends Endocrinol Metab 15: 139–142

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Professor of Medicine at Monash University, a Senior Fellow at Prince Henry's Institute, Monash Medical Centre, Melbourne, and a Professorial Associate of the Centre for Neuroscience, University of Melbourne, Australia

    John W Funder

Authors
  1. John W Funder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John W Funder.

Ethics declarations

Competing interests

Dr Funder is a consultant for Eli Lilly, Merck, Pfizer, cBio, Exelisis, GNF and Kalypsis, and holds research grants from Merck and Pfizer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Funder, J. Mineralocorticoid-receptor blockade, hypertension and heart failure. Nat Rev Endocrinol 1, 4–5 (2005). https://doi.org/10.1038/ncpendmet0016

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0016

  • Springer Nature Limited

This article is cited by

Search

Navigation